Here is our brief magic mushroom industry outlook in hopes that it will help inform your investing decisions. Magic mushrooms are defined by USDA as any species that contains psilocybin. The most common psychedelic mushrooms are Psilocybe cubensis as this strain has over 100 sub strains.
There are an estimated 209 species of trippy mushrooms, which mainly fall into two broad groups. The psilocybes, containing psilocybin and psilocin, are the friendlier magic mushrooms.
The second type is the amanita. The best known is the fly-agaric, Amanita muscaria, the red-and-white-spotted mushroom familiar from storybooks, the favored resting stool of gnomes. The amanitas are more myth-ridden than the psilocybes, and their psychic results more unpredictable.
THE PAST
The modern magic mushroom industry is still extremely young in North America. The Summer of Love of 1967 and the resultant popularization of the hippie culture to the mainstream popularized psychedelia in the minds of pop culture, where it remained dominant through the 1970s.
But how did this happen?
Thanks to Mr. Gordon Wasson, an ex-vice president of J. P. Morgan & Company, whose hobby and obsession was mushrooms. In 1955 he traveled to Oaxaca, Mexico, where he met Señora Sabina, a Mazatec Indian, who introduced him to magic mushrooms and mysticism. On his first shroom trip, he felt “as if his soul had been scooped out of his body.” Wasson kick-started the psychedelic movement, according to Letcher, when he wrote an article in 1957 for Life magazine entitled “Seeking the Magic Mushroom.”
THE NOW
Demand for magic mushrooms is rapidly rising, as consumers look to other avenues for therapeutic relief and spiritual awareness.
As of 2 years ago, the Food and Drug Administration (FDA) has given the hallucinogenic compound psilocybin, known for giving “magic mushrooms” their mind-altering powers, a “Breakthrough Therapy” designation. Since then, there have been a number of studies done by MAPS on the medicinal and therapeutic advantages of Psilocybin.
This has led to progress towards legalization. And thanks to the legalization of cannabis, this is probably going to happen pretty fast. Our bet is that it first happens in a few American states, then all of Canada, and then we see what happens with federal legalization in the USA.
The psychedelic marketplace is forecasted to be nearly a $6.9 billion business by 2027.
Here are 3 psychedelic stocks that we recommend watching. As it would be like investing in Tilray or Aurora before the big cannabis stock boom!
Aion Therapeutic (CSE:AION)
In addition to its recent move into the psychedelics arena, Aion Therapeutic operates in the cannabis industry with a licensed production line in Canada.
As far as its psychedelics business goes, the company’s lead, Dr. Stephen D. Barnhill, has said Aion is pursuing novel formulations of various natural compounds, including psilocybin and fungi.
Better Plant Sciences (CSE:PLNT,OTCQB:VEGGF)
This wellness firm has a substantial investment in the psychedelics market thanks to a majority ownership stake in NeonMind Biosciences, previously known as Flourish Mushroom Labs. According to its parent company, NeonMind will carry out clinical trials on the therapeutic effects of psilocybin.
NeonMind plans to eventually launch branded products such as mushroom-infused items designed to “support immune, cognitive, memory and other brain functions.”
Captiva Verde Land (CSE:PWR)
This cannabis and hemp company secured an entry point in the psychedelics space by forming a partnership with a Mexican company capable of distributing pharmaceutical and wellness products, including psychoactive and non-psychoactive drugs.
THE FUTURE
YOUR ARE EARLY. IN OUR OPINION THE TIME TO INVEST IS NOW!
Lets start with mental health and healing. We could talk all day about psilocybe mushrooms, but for now a paragraph will do. Johns Hopkins University is leading the charge in taking “magic mushrooms” out of the medieval dungeons they were placed in during the 1960’s to reveal the opportunities for working with these mushrooms. One study they looked at was improving depression and anxiety in terminally ill cancer patients. After a single session with psilocybin mushrooms, eighty percent of participants reported a significant reduction in depression and anxiety six months later.
Psilocybin mushrooms are also being explored for their ability to help decrease addiction, cope with PTSD, reduce anxiety and depression, and connect with god. In November of 2018, there was even a study conducted looking at the scheduling of this mushroom, which is currently a Schedule 1 drug.
A Schedule 1 drug is classified as having “no currently accepted medical use and a high potential for abuse” (DEA, 2019) Confirming what many have known all along, based on the 8 factors of controlled substances, the scientists recommended it be switched to a Schedule 4 drug, similar to prescription sleeping aids. Shout out to Oakland, CA and Denver, CO, the first cities to decriminalize psilocybin in 2019.
Resources
https://www.popsci.com/story/health/psilocybin-magic-mushroom-fda-breakthrough-depression/
1 comment
Comments are closed.